CTS Capital
VC Fund
CTS Capital is a healthcare-focused fund investing in the top players of the medical vertical sector including ininnovative biotechnology, medicine, medical device and service, who has strong ability in the integration of industry resources. Currently CTS Capital manages multiple funds in both US Dollar and RMB, and the core members are fromtop-tier PE funds and healthcare MNCs, with extensive experience in both healthcare and private equity industries.
- Total investments:
- 19
- Last investment:
- Lead investor:
- 5%
Last updated:
For AI agents: llms.txt
Industries CTS Capital invests in
Stages CTS Capital invests in
Countries CTS Capital invests in
Investment Focus
Industry
- Medical 11 (58%)
- Health Care 11 (58%)
- Biotechnology 10 (53%)
- Biopharma 8 (42%)
- Pharmaceutical 5 (26%)
Stage
- Series A 7 (37%)
- Series C 5 (26%)
- Series B 4 (21%)
- Seed 1 (5%)
- Series D 1 (5%)
Country
- China 15 (79%)
- Hong Kong 1 (5%)
- United States 1 (5%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Cornerstone Robotics
|
Cornerstone Robotics operates to improve the accessibility of high-end medical services in China. | $70M / Series C / Jan 13, 2025 | |
Bio-Link
|
Bio-Link is a drug development company that offers solutions for the life science industry. Bio-Link was founded in 2001 and was headquartered in Shanghai, China. | Series A / Feb 21, 2024 | |
Pixel Biosciences
|
Pixel Biosciences provides cutting-edge technologies for targeted RNA and DNA research and studies | Seed / Jan 01, 2024 | |
|
Cornerstone Robotics
|
Cornerstone Robotics operates to improve the accessibility of high-end medical services in China. | $110.3M / Series B / Jun 30, 2023 | |
Eccogene
|
Eccogene is a Health Care Company. | $25.2M / Series B / Jun 12, 2023 | |
Caremo
|
Caremo provides customizable pharmaceutical R&D solutions for global biotechnology and pharmaceutical companies. | $14.5M / Series A / Apr 18, 2023 | |
Med-Zenith
|
Meditop Medical Technology is a provider of medical devices and solutions for cardiovascular diseases. They provide disease treatment solutions based on the etiology and condition. It also offers solutions to congenital heart disease, arrhythmia, and valve disease. | Series C / Mar 13, 2023 | |
WuXi Bo Rui Biotechnology
|
Suzhou WuXi Bo Rui Biotechnology is a radioactive molecular imaging and nuclear drug transformation platform. | $42M / Series A / Sep 02, 2022 | |
Intellective Bio
|
Intellectual Bio specializes in the fields of biopharmaceutical development, commercial production, and Biologics Development. IntellectiveBio is equipped with technical platforms including Protein Science, Cell Engineering, Cell Culture, Protein Purification, Analytical Science, Formulation Development | $74.1M / Series C / Aug 04, 2022 | |
OriginCell
|
OriginCell is a biomedical equipment enterprise that develops tumor immuno-therapy solutions. It develops tumor therapies and cellular drugs through the use of the 10-phage display library, humanized antibody technology platform, and antibody discovery platform that enable their medical facilities to apply in cancer treatments.OriginCell wasfounded in 2014 and is headquartered in Shanghai, China. | $120M / Series B / Aug 01, 2022 | |
| See all 19 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does CTS Capital invest in?
CTS Capital invests primarily in Medical, Health Care and Biotechnology startups, most often at Series A and Series C stage. Most of the 19 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did CTS Capital last invest?
The most recent investment recorded for CTS Capital closed in Jan 2025. Shizune tracks 19 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
